Novaliq Announces FDA Approval of VEVYE™ (Cyclosporine Ophthalmic Solution) 0.1% for the Treatment of the Signs and Symptoms of Dry Eye Disease
Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE™ (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease. VEVYE (development name CyclASol®) is the first and only cyclosporine solution indicated for the treatment of signs and symptoms of dry eye disease with efficacy demonstrated after 4 weeks of treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005090/en/
Novaliq Announces FDA Approval of VEVYE™ (Cyclosporine Ophthalmic Solution) 0.1%, for the Treatment of the Signs and Symptoms of Dry Eye Disease (Photo: Business Wire)
“We are proud that FDA approved VEVYE. The safety and efficacy of VEVYE were assessed in a total of 1369 patients with dry eye disease, of which 738 received VEVYE. VEVYE and its novel vehicle were safe, well tolerated, and demonstrated early, consistent, and durable therapeutic effects,” said Sonja Krösser, PhD, Vice President Medical Science & Regulatory Affairs at Novaliq. “It is an exciting moment when you have followed science that finally led into a new category of water-free ocular therapies addressing unmet medical needs for patients suffering from dry eye disease.”
Dry eye disease (DED) affects millions of Americans and is one of the most common ocular surface disorders. A leading cause of DED is inflammation of the ocular surface. The chronic inflammatory nature causes progressive corneal surface damage that can lead to direct or indirect visual impairment.
VEVYE is cyclosporine, solubilized in a novel, water-free excipient and was designed to address unmet needs, providing patients with a fast acting and well tolerable dry eye drug therapy. The solution does not contain water or anti-microbial preservatives, oils or surfactants. As a water-free product, there is no associated pH and no osmolarity.
"VEVYE addresses the well documented underlying inflammatory root cause of dry eye disease, repeatedly demonstrating early and clinically meaningful efficacy upon both signs and symptoms,” said John D. Sheppard, MD, MMSc, FACS, professor of ophthalmology at Eastern Virginia Medical School, and Mid-Atlantic Medical Director for Eye Care Partners and investigator in the development program. “The clinical trials consistently showed significant therapeutic improvements in ocular surface damage and associated symptoms, while pioneering visual function improvement analysis. VEVYE is an exceptionally well tolerated formulation, combining a novel, first-in-class vehicular delivery system with by far the most established and safe topical active pharmaceutical ingredient, cyclosporine, providing a major advancement for our patients.”
“I am thrilled that a novel water-free, non-preserved pharmaceutical option for the treatment of the signs and symptoms of dry eye was approved by the FDA,” commented Jade Coats OD, optometric physician at McDonald Eye Associates, Rogers, Arkansas and member of the Intrepid Eye Society. “With the most potent commercially available cyclosporine 0.1%, VEVYE brings to the table excellent comfort and tolerability, fast onset of symptom relief, and a strategically effective drop size, providing patients and practitioners an additional anti-inflammatory, immunomodulating option for the treatment of dry eye disease.”
“The US FDA approval of VEVYE marks a milestone for patients and care takers by addressing a significant unmet need for millions of people suffering with this disease,” said Christian Roesky, PhD, CEO Novaliq. “With now two EyeSol® based and water-free dry eye drug therapies approved by FDA Novaliq has established a novel category of non-aqueous, non-preserved ophthalmic drugs with the opportunity to become a standard of care in ophthalmology in the future. We will continue to execute on our mission to transform ocular therapies by developing breakthrough novel EyeSol® therapies way beyond dry eye disease.”
About VEVYE™ (cyclosporine ophthalmic solution) 0.1%
VEVYE (cyclosporine ophthalmic solution) 0.1%, for topical ophthalmic use.
INDICATIONS AND USAGE
VEVYE is indicated for the treatment of the signs and symptoms of dry eye disease.
WARNINGS AND PRECAUTIONS
Potential for Eye Injury and Contamination. To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
Use with Contact Lenses. VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of VEVYE ophthalmic solution.
Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).
Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click [here] for full Prescribing Information for VEVYE.
Novaliq is a biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology. Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases. On May 18th, 2023, U.S. Food and Drug Administration (FDA) approved MIEBO™ (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) followed by the approval of VEVYE™ (cyclosporine ophthalmic solution, development name CyclASol®) 0.1% on May 30th, 2023. Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies. More on www.novaliq.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Novaliq Media Contact:
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nippon Sanso Holdings Corporation: Publication of “Integrated Report 2023”26.9.2023 09:00:00 EEST | Press release
Nippon Sanso Holdings Corporation (NSHD) issued our “Integrated Report 2023” on our website on September 26. Our Integrated Report is published every year to provide an annual report on the Group's Financial information including management strategies and business overview as well as non-financial information including sustainability activities to all the stakeholders including our group members as well as investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230925112298/en/ Integrated Report 2023 cover page (Graphic: Business Wire) In “Integrated Report 2023,” we have focused on our medium-term management plan "NS Vision 2026| Enabling the Future" ("NS Vision 2026") announced in May 2022 with the aim of explaining the value creation story in an easy-to-understand manner, using specific examples. The "Integrated Report 2023" is published in PDF format, and we added jump link to certain pages on our website containing re
D3 Security’s European Team to Bring Smart SOAR to it-sa Expo&Congress26.9.2023 05:00:00 EEST | Press release
D3 Security, the leader in smart security orchestration, automation, and response (SOAR), today announced it will be demonstrating its Smart SOAR platform at it-sa Expo&Congress, happening 10-12 October, 2023, at the Exhibition Centre in Nuremberg, Germany. The D3 Security team will be at Booth 251 in Hall 7. “D3 is coming to Germany’s leading IT security event because we have the ideal SOAR solution for companies based in Germany, as well as the rest of Europe,” said Amardeep Dhingra, Director of Strategic Alliances at D3 Security. “We already work with world-class automotive, financial services, and managed services clients—all of which are prevalent industries in the German market—so German companies can be confident in our ability to meet their security automation needs.” D3 Security’s growing footprint in Europe includes sales, sales engineering, and system engineering staff, some of whom are based in Germany. D3 Security’s European customers include the Danish managed security se
MOGAS Systems & Consulting Modules Offer Safe and Reliable Solutions for Heavy Oils Refining26.9.2023 04:00:00 EEST | Press release
MOGAS Industries, Inc. (MOGAS) proudly offers the latest feat in engineering for heavy oils refining. MOGAS Systems & Consulting (MS&C) modular units (modules) are fully functional and ready for use in many process plants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230925096331/en/ MOGAS Systems and Consulting modular unit (Photo: Business Wire) Modules are a favorable choice compared to traditional stick-built (site fabricated) refinery units constructed on-site, which are frequently more expensive and require excessive additional construction costs due to unnecessary pipe, welding, fittings and other components. MS&C modules’ streamlined design provides many benefits to operators, including reduced capital and operations expenditures (CAPEX and OPEX). MOGAS recently produced five high pressure letdown module units for a residue upgrade application, lowering operations risks to personnel and streamlining the unit’s proc
STEMCELL Technologies Partners with Science World to Empower Girls Pursuing Science-related Careers25.9.2023 21:02:00 EEST | Press release
STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce it will be the presenting partner of the Girls and STEAM Summit at Science World in Vancouver. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230925955247/en/ STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce it will be the presenting partner of the Girls and STEAM Summit at Science World in Vancouver, British Columbia. The Summit, which takes place on November 4, 2023, is a full-day event with workshops, hands-on activities, a keynote presentation, and sessions with experienced mentors who work in STEAM (science, technology, engineering, art and design, and math). “Science is about so much more than what happens in the laboratory. It provides a lens that can instill a deep-seated curiosity in young minds and enrich every aspect of our lives,” said Sharon Louis, Senior Vice President of Research and Devel
AngloGold Ashanti plc Completes the Primary Listing of Its Ordinary Shares on the NYSE and Commences Trading25.9.2023 17:11:00 EEST | Press release
AngloGold Ashanti is pleased to announce that it has today completed its corporate restructuring, with a primary listing of its shares on the New York Stock Exchange (NYSE) and a corporate domicile in the UK. The corporate restructuring was first announced on 12 May of this year and approved by the shareholders of AngloGold Ashanti Limited on 18 August. “The move of our primary listing to the NYSE provides us with improved access to the world’s largest capital market and places us alongside the industry’s highest-valued gold companies,” said AngloGold Ashanti CEO Alberto Calderon. “This signifies an important new era for AngloGold Ashanti strengthening our corporate infrastructure as we continue to focus on taking performance from our world class asset base to the next level.” The ordinary shares of AngloGold Ashanti plc commenced trading on the NYSE today, 25 September 2023, maintaining the ticker symbol AU. Trading in the AngloGold Ashanti Limited American Depositary Shares (ADSs) on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom